Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults
CHENGDU, China, Sept.12, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") ofChina has recently approved the new drug application for Stapokibart (anti-IL-4Rα monoclonal antibody, trade name:Kangyueda (康悦达), for th...
Keymed Biosciences Announces Interim Results for First Half of 2024
CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) * In June 2024, the long-term e...
Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM
CHENGDU, China, June 20, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled "A Novel Anti-CD38 Monoclonal Antibody for T...
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis
CHENGDU, China, June 2, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis (AD) has been released by way of oral presentation...
Keymed Biosciences Announces 2023 Annual Results and Business Updates
* Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by theChina's NMPA and granted priority review. * Advanced a Phase III clinical study of Stapokibart for the treatment of CRSwNP in 2023. The results of t...
Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration
CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, proactively carry out global strategic collaboration and a...
Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901
CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class C...
Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM
CHENGDU, China, Jan. 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is pleased to announce that the latest data from the Phase Ia dose-escalation trial of CMG901 (Claudin 18.2 antibody drug conjugate), a novel drug candidate, for advanced solid tumors will be presented as...
China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer
CHENGDU, China, Sept. 22, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX:02162) announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted CMG901 the Breakthrough Therapy Designation for the treatment of advanced gastric and gastroe...
Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350
CHENGDU, China, June 10, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced today that the first patient has been dosed in the Phase I trial of CM350. CM350 is a GPC3xCD3 bispecific antibody developed by the Company for the treatment of solid tumors. The phase I trial is being conduc...
FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies
CHENGDU, China, April 19, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relap...
CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States
CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by t...
Keymed Biosciences Releases 2021 Annual Results
CHENGDU, China, March 30, 2022 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX Code: 02162) released 2021 annual results. BUSINESS HIGHLIGHTS On July 8, 2021, Keymed was listed on the HKEX. During the Reporting Period, the Company continued proceeding the R&D of products and made the following p...
Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect
CHENGDU, China, March 7, 2022 /PRNewswire/ -- Keymed Biosciences Inc. (2162.HK) is pleased to announce that the shares of the Company have been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect with effect fromMarch 7, 2022, pursuant to the announcement issued by the Shenzhen St...
Keymed Bio Joins Hang Seng Family of Indexes
HONG KONG, Feb. 18, 2022 /PRNewswire/ -- According to the quarterly review results of Hang Seng Family of Indexes, Keymed Biosciences Inc. (2162. HK) was included a constituent stock of: * Hang Seng Composite Index; * Hang Seng Small Cap (Investable) Index; * Hang Seng Stock Connect Hong K...
